Avinasi Labs is building the world’s first liquid foundation model for longevity. We are creating an AI-native, incentive-aligned network that transforms human aging biology into a liquid market for targets, biomarkers, and therapies. Our proprietary FM + AI agents (trained on 2.5M samples) accelerate discovery 6× faster than human scientists, compressing timelines from years to months. Backed by ClockBase, MethylGPT, and our agentic AI scientist led by co-founder Dr. Albert Kejun Ying (Harvard/Stanford, creator of MethylGPT), and Winnie Qiu (MIT engineer, serial founder with 10+ years in health data & hardware), Avinasi Labs has signed LOIs with AI drug discovery and pharma partners, grown a 55K+ community in under 6 months, and secured collaborations with Harvard and Stanford. Our advisors include leaders experts from Harvard, Stanford, AstraZeneca, McKinsey, and VitaDAO. With $8.5B invested in longevity in 2024, pharma deals validating AI ($3B Lilly/Novartis × Isomorphic), and strong policy tailwinds, Avinasi Labs is positioned to lead the automation of longevity science.
